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Abstract 
Primary adenocarcinoma of the bladder is a
rare tumor. The classification between primary
vesical and urachal is debated. We present the
case of a young female who presented clinico-
pathological  features  of  a  metastatic  urachal
adenocarcinoma,  but  the  histological  result
revealed primary adenocarcinoma of the bladder
contrary to expectancy. To the best of our knowl-
edge this is the first reported case of a metasta-
tic adenocarcinoma of the bladder in a 25 years
old female. This case emphasizes the challenge
for  urologists  to  recognize  and  manage  this
aggressive tumor in the setting described.
Introduction
Pure  adenocarcinoma  of  the  bladder  is  a
rare tumor accounting for 0.5-2% of all bladder
cancers.1 It  is  classified  in  primary  vesical,
urachal and metastatic. The incidence of pri-
mary  adenocarcinoma  is  greater  in  areas
where bilharziasis is endemic (5-11.4% of all
bladder  tumors)  and  in  adult  exstrophy
patients (4%).2,3 It is more common in patients
over 50 years old. The rate of extravesical dis-
ease  at  diagnosis  is  higher  compared  to
urothelial carcinoma because it is often a soli-
tary lesion, has predilection for local invasion
and symptoms are late. Clinical presentation is
similar to others bladder tumors with hema-
turia, suprapubic pain and voiding difficulties
being the most common symptoms. Diagnosis
is  made  by  cystoscopy,  urinary  cytology  and
transurethral resection of the baldder. 
The pathogenesis is different: the urachal
adenocarcinoma arises from the remnant of
the embryonic allantoic stalk, which connects
the  umbilicus  to  the  fetal  bladder.  Conse  -
quently, the location of the tumor is always at
the dome of the bladder whereas primary ade-
nocarcinoma of the bladder arises from meta-
plastic changes of unstable urothelium, poten-
tially from any portion of the bladder.4,5 Some
classifications  have  been  suggested.  Most
widely used, the Sheldon’s classification has
restrictive criteria. Tumor located at the dome
of the bladder, absence of cystitis glandularis
and  cystitis  cystica,  primary  involvement  of
muscle  or  deeper  structures,  clear  demarca-
tion between tumor and normal urothelium,
presence  of  urachal  remnant  in  association
with  the  neoplasm  and  extensions  of  the
tumor to the space of Retzius are all consid-
ered as necessary criteria to classify a tumor
as an urachal adenocarcinoma.6 Other classifi-
cations use less restrictive criteria considering
a mass arising from the dome of the bladder as
adenocarcinoma  of  urachus  unless  a  transi-
tion between normal urothelium and adeno-
carcinoma is proved.7
We report a first case of a young female with
a metastatic primary vesical adenocarcinoma
to liver and lung at the time of diagnosis. This
case emphasizes the challenge for urologists
to differentiate urachal and primary adenocar-
cinoma of the bladder preoperatively.
Case Report
A 25 years old female patient without prior
medical history was referred to our hospital for
painless  hematuria.  Blood  tests  and  physical
examination  were  normal.  At  cystoscopy,  a
bleeding necrotic mass arising from the bladder
dome was found without any other lesion of the
urothelium. Cytology revealed an adenocarcino-
ma.  A  computed  tomography  (CT)  scan  con-
firmed the mass of the bladder dome extending
to the abdominal wall and showed multiple liver
metastases and one pulmonary metastasis of the
right lower lobe (Figure 1). Urachal adenocarci-
noma was suspected because of the typical local-
ization of the primary tumor. A partial cystecto-
my with en bloc urachectomy up to the umbili-
cus and bilateral pelvic lymph node dissection
was  performed.  Histological  results  showed  a
muscle-invasive mucinous adenocarcinoma, 7.5
cm in length, without infiltration of urachal rem-
nants (Figure 2). Because of the presence of
glandular cystitis, villous adenoma with intestin-
al metaplasia and absence of tumoral infiltration
of the urachus, the tumor was considered as a
primary vesical adenocarcinoma (Figure 3). Two
abdominal but no pelvic lymph node were invad-
ed. TNM staging was pT3a, pN2, M1, G2-3, R0.
Since the tumor presented histological features
of the digestive tract, a palliative chemotherapy
protocol consisting in bevacizumab, oxaliplatin,
5-fluorouracil and folinic acid was started.
CT scan at 3, 6, 9, 12 and 15 months showed
regression of hepatic metastases, unchanged
pulmonary metastasis and no new metastasis
while treated with 5 fluoro uracil, bevacizumab
and folinic acid.
Discussion
Urachal and primary vesical adenocarcino-
ma are two different tumors, but the impor-
tance of this distinction for the management
and survival is debated. Urachal adenocarci-
noma seems to have better survival rate than
primary  vesical  adenocarcinoma.  Unfortu  -
nately, heterogeneity exists in published data,
with regards to treatment modalities (margin
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Figure  1.  Computed  tomography  scan
shows  a  mass  arising  from  the  bladder
dome,  compatible  with  a  cancer  of  the
urachus.[Rare Tumors 2011; 3:e9] [page 29]
status, adjuvant therapy, extent of node dis-
section)  and  patient’s  inclusion  criteria.
Therefore, careful interpretation of results is
needed.2,7 Because  of  the  anatomical  differ-
ence, surgical management is different: radi-
cal cystectomy is performed for primary blad-
der adenocarcinoma whereas partial cystecto-
my with en bloc urachectomy up to the umbili-
cus  is  considered  the  gold  standard  for  the
treatment  of  urachal  carcinoma.  Staging  at
cystectomy is considered the strongest predic-
tor of mortality. Reported 5-year overall sur-
vival rate is poor because the diagnosis is late
when the tumor is often locally advanced and
has  spread  systemically.  Moreover  adjuvant
treatment has low efficiency. Adenocarcinoma
is known to be radioresistant and there is no
approved chemotherapy protocol.8-10
The case of this patient is very unusual for
her age and clinical history. The radiological
and clinical features mimicked an adenocarci-
noma  of  the  urachus.  The  pathologic  result
was unexpected. The operation performed was
not the procedure normally performed in pri-
mary adenocarcinoma of the bladder. In this
situation, with the patient’s consent, palliative
chemotherapy  was  undertaken.  After  a  15
month follow-up, the patient is free from local
recurrence  or  new  metastasis  contrary  to
expectancy. Nevertheless since surgical man-
agement  is  different  for  urachal  and  non
urachal  adenocarcinoma,  we  believe  that
when a mass at the dome of the bladder is
found, an extensive transurethral resection of
the bladder should be always performed to dif-
ferentiate these two close tumors. 
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Case Report
Figure 2. Gross appearance of the tumor
which measured 7.5 cm of length with no
involvement of the abdominal wall.
Figure 3. Glandular cystitis adjacent to a
villous adenoma with high grade dysplasia
and infiltrating adenocarcinoma.